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Abstract
Purpose:Deregulated expression of miRNAs has been shown in multiple myeloma (MM). A promising
strategy to achieve a therapeutic effect by targeting themiRNA regulatorynetwork is to enforce the expression
of miRNAs that act as tumor suppressor genes, such as miR-34a.
Experimental Design: Here, we investigated the therapeutic potential of synthetic miR-34a against
human MM cells in vitro and in vivo.
Results: Either transient expression of miR-34a synthetic mimics or lentivirus-based miR-34a-stable
enforced expression triggered growth inhibition and apoptosis in MM cells in vitro. Synthetic miR-34a
downregulated canonic targets BCL2, CDK6, and NOTCH1 at both the mRNA and protein level. Lentiviral
vector-transduced MM xenografts with constitutive miR-34a expression showed high growth inhibition in
severe combined immunodeficient (SCID) mice. The anti-MM activity of lipidic-formulated miR-34a was
further shown in vivo in two different experimental settings: (i) SCID mice bearing nontransduced MM
xenografts; and (ii) SCID-synth-hu mice implanted with synthetic 3-dimensional scaffolds reconstituted
with human bone marrow stromal cells and then engrafted with human MM cells. Relevant tumor growth
inhibition and survival improvement were observed in mice bearing TP53-mutated MM xenografts treated
with miR-34a mimics in the absence of systemic toxicity.
Conclusions: Our findings provide a proof-of-principle that formulated synthetic miR-34a has thera-
peutic activity in preclinicalmodels and support a framework for development ofmiR-34a–based treatment
strategies in MM patients. Clin Cancer Res; 18(22); 6260–70. 2012 AACR.
Introduction
Multiple myeloma (MM) is the second most common
hematologic malignancy in Western countries. Despite
advances in the understanding of MM pathobiology and
development of novel therapeutic strategies, available treat-
ments fail to cure the disease in most cases (1–3). A variety
of genetic and epigenetic abnormalities characterizes the
MMmultistep transformationprocess occurring in thebone
marrow (BM), where the BM microenvironment (BMM)
plays a key supportive role for growth, survival, and drug
resistance of tumor cells (1, 4–6). All these alterations can
dramatically deregulate the plasma cell growth and the
network ofmolecular interactions within the human BMM.
miRNAs are small noncoding RNAs of 19 to 25 nt that
play a critical role in the posttranscriptional regulation of
gene expression (7, 8). As a result of imperfect pairing with
target mRNAs, they may cause repression of translation or
degradation of mRNAs. These small molecules are impor-
tant modulators of key regulatory cellular pathways and
may play a relevant role in tumorigenesis (9), as deregulated
miRNAs can act as oncogenes (Onco-miRNAs) or tumor-
suppressors (TS-miRNAs; refs. 10, 11). Therefore, miRNAs
have elicited a growing interest in the cancer research
community as new potential tumor cell targets (Onco-
miRNAs) or as new potential anticancer agents (TS-miR-
NAs), because of their ability to target multiple genes in the
context of signaling networks involved in cancer promotion
or repression (12). Specifically, miRNAs are variably
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involved in the pathogenesis of human MM and several
miRNAs have been found to be abnormally upregulated or
downregulated in primary MM cells or cell lines, as recently
reviewed (13–16). Although the biologic role of miRNAs in
the pathogenesis of MM is presently well documented by
several studies, only few reports support the notion that
miRNAs have a potential in MM therapy (16–18). For
example, Roccaro and colleagues (17) showed a down-
regulation of 15a/16 miRNAs in MM. Because these miR-
NAs appear to be negative regulators of MM cell prolifer-
ation by inhibiting AKT3, ribosomal protein S6, MAP
kinases, and NF-kappaB activator MAP3KIP3, it was sug-
gested that the reconstitution of normal miRNA expression
could represent a MM treatment. More recently, Pichiorri
and colleagues (18) showed a MM-specific miRNA signa-
ture characterized by miR-192, 194, and 215 downregula-
tion in a subset of newly diagnosedMMs. ThesemiRNAs are
transcriptionally activated by TP53 and are also positive
regulators of TP53, thereby producing a loop of major
relevance in the biology of MM, which can be a potential
target for therapeutic intervention.
AmongmiRNAs frequently deregulated in human cancer,
miR-34a is of special interest in the field of miRNA thera-
peutics (19–21). Specifically, hypermethylation ofmiR-34a
promoter has been found in MM patient cells and MM cell
lines, but not in normal counterparts (22). miR-34a, first
described as potential TS-miRNA (23), belongs to amiRNA
family includingmiR-34b andmiR-34c and is encoded by a
gene located on 1p36 (21). miR-34a transcription is
induced by TP53 in response to cell stress, thereby promot-
ing apoptosis, cell-cycle arrest, and senescence (24–29).
Recent reports show that induction of miR-34a expression
could overcome TP53 loss of function in pancreatic cancer
cells (22, 30). Although some of these eventsmay, at least in
part, be related to the positive feedback loop that linksmiR-
34a to TP53 (31), some reports suggest that the antitumor
activity of miR-34a might be independent of TP53 muta-
tional status (32, 33). Moreover, in one report miR-34a
antitumor activity is not limited to cell lines with reduced
endogenous miR-34a expression levels, but it is also effec-
tive in cells with an apparently normal miRNA expression
(33).
In this study,we investigated anovel anti-MM therapeutic
strategy based on miR-34a. The main challenges for an
effectivemiRNA-based therapy include the effective delivery
of the appropriate miRNA to and its uptake by malignant
plasma cells in their specificmicroenvironmentwithout off-
target effects. Therefore, we characterized the in vitro and in
vivo anti-MM activity and molecular perturbations pro-
duced by synthetic miR-34a mimics. For in vivo studies,
synthetic miR-34a mimics were formulated in a novel
neutral lipid emulsion (NLE; refs. 33, 34) delivery system
and, to explore the clinical translatability of experimental
findings, we examined the antitumor activity in murine
xenograft models of human MM. Our findings support the
development of formulated miR-34a as an experimental
new agent for the treatment of MM.
Materials and Methods
Cell lines and primary cultures
NCI-H929, U266, and SKMM1 MM cell lines were avail-
able within our research network, although the RPMI-8226
MM cell line was purchased from Istituto Zooprofilattico
Sperimentale (I.Z.S.L.E.R.). OPM1, DOX-6, and LR-5 MM
cell lines were kindly provided by Dr. Eduard Thomson
(University of Texas Medical Branch, Galveston, TX, USA),
MM1SwaspurchasedbyAmericanTypeCultureCollection,
INA-6 was provided by Dr. Renate Burger (University of
Erlangen-Nuernberg, Erlangen, Germany; refs. 35, 36).
Human BM stromal cells (BMSC) were obtained by long-
term culture of BM mononuclear cells, as previously
described (37–39). Primary CD138þ patientMMcells were
obtained by Ficoll gradient separation followed by positive
selection from patient BM aspirates, using CD138MicroBe-
ads antibody (MACS, Milteny Biotec). For coculture, 1 
105 CD138þ cells were seeded on 5  104 BMSCs, which
had been cultured for 24 to 48 hours in 96-well plates.
In vitro transfection of MM cells with syntheticmiR-34a
Synthetic pre-miRNAs were purchased from Ambion
(Applied Biosystems). A total of 1  106 cells were electro-
porated with scrambled (miR-NC) or synthetic pre-miR-
34a (miR-34a) at a final concentration of 100nmol/L, using
Neon Transfection System (Invitrogen) with 1050 V, 30ms,
1 pulse. Cell transfection efficiency was evaluated by flow
cytometric analysis of FAM-dye-labeled synthetic miRNA
inhibitor (Invitrogen) transfection.
Quantitative real-time amplification of miRNAs and
mRNAs
Total RNA from MM cells was prepared with the TRIzol
Reagent (Invitrogen) according to manufacturer’s instruc-
tions. Oligo-dT-primed cDNA was obtained using the
High Capacity cDNA Reverse Transcription Kit (Applied
Translational Relevance
The miRNA regulatory network is emerging as a novel
target for the treatment of human cancer. In this study,
we investigated the therapeutic potential of synthetic
miR-34a against TP53-mutated human multiple myelo-
ma (MM) cells in vitro and in vivo. The translational
relevance of our study resides in the findings that intra-
tumor or systemic delivery of novel lipidic-formulated
synthetic miR-34a induces antimyeloma activity in vivo
in differentmurinemodels of humanMM, including the
most innovative SCID-synth-hu system, in the absence of
systemic toxicity in treated animals. Moreover, the spec-
ificity of the miR-34a in vivo activity was shown by
selective downregulation of canonic targets BCL2 and
CDK6. Taken together, our results indicate that formu-
lated synthetic miR-34a is an active agent against MM,
which merits further investigation for clinical develop-
ment in this still incurable disease.
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Biosystems). The single-tube TaqMan miRNA assays were
used to detect and quantify mature miR-34a and target
mRNAs, according to the manufacturer’s instructions by
the use of the StepOne Thermocycler and the sequence
detection system (Applied Biosystems). miR-34a and
mRNAs were normalized on RNU44 (40) and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH; Ambion),
respectively. Comparative real-time PCR (RT-PCR) was
conducted in triplicate, including no-template controls.
Relative expression was calculated using the comparative
cross-threshold (Ct) method (41).
Apoptosis analysis
MM cells transfected or transduced with miR-34a or
scrambled sequence/empty vector were harvested and trea-
ted with Annexin V/7-aminoactinomycin D (7-AAD) solu-
tion (BDPharmingen) at 24, 48, and 72 hours, according to
the manufacturer’s instructions.
Animals and in vivo models of human MM
Male CB-17 severe combined immunodeficient (SCID)
mice (6 to 8 weeks old; Harlan Laboratories, Inc.) were
housed and monitored in our Animal Research Facility. All
experimental procedures and protocols had been approved
by the Institutional Ethical Committee (Magna Graecia
University) and conducted according to protocols approved
by the National Directorate of Veterinary Services (Italy). In
accordance with institutional guidelines, mice were sacri-
ficed when their tumors reached 2 cm in diameter or in the
event of paralysis or major compromise in their quality of
life, to prevent unnecessary suffering. Forour study,weuse 3
different models of human MM, including (i) SCID mice
bearing lentiviral vector-transduced MM xenografts; (ii)
SCID mice bearing subcutaneous MM xenografts (42); and
(iii) SCID mice implanted with a 3-dimensional polymeric
scaffold previously reconstituted with human BMSCs and
then injected with human MM cells (SCID-synth-hu;
refs. 43–45).
Statistical analysis
Student t test, 2-tailed, and Log rank test were used to
calculate all reported P values using GraphPad software
(www.graphpad.com). Graphs were obtained using Sigma-
Plot version 11.0.
Results
Expression of miR-34a in MM cells
Wefirst evaluated themiR-34a expression in a series of 11
MMcell lines by quantitative RT-PCR (q-RT-PCR; for details
about MM cell lines, see Supplementary Methods). Among
these, 2 wild-type TP53 cell lines (MM1S and NCI-H929)
showed significantly higher miR-34a expression as com-
pared with TP53-mutated MM cells (U266, SKMM1, RPMI-
8226, INA-6, DOX6, KMS12-PE, OPM1, OPM2, and
LR5; Fig. 1A). We next explored if the positive miR-34a-
TP53 loop was functional in MM cells. Specifically, we
treated the TP53 mutated SKMM1 and RPMI-8226 cells, as
well as the TP53wild-typeNCI-H929 cell linewith nutlin-3,
which blocks the TP53-MDM2 inhibitory interaction and
thereby induces the expression of TP53-regulated genes
(46). As expected, nutlin-3 treatment induced miR-34a
expression in TP53 wild-type cells (NCI-H929) but not in
TP53-mutated SKMM1 and RPMI-8226 cells, as evaluated
by q-RT-PCR (P < 0.05, Fig. 1B). Nutlin-3–induced upre-
gulation of miR-34a in turn reduced expression of miR-34a
canonical targets, such as BCL2 and CDK6 proteins (for
Western blotting procedures see Supplementary Methods).
As expected, this effect was not demonstrable in TP53-
mutated RPMI-8226 cells (Fig. 1C). These findings suggest
that miR-34a expression is positively modulated by a func-
tional loop in TP53 wild-type MM cells. An additional
finding reinforcing the role of TP53 in regulation of miR-
34a expression is the significantly downregulated expres-
sion of miR-34a in a microarray data set of TP53-mutated
CD138þ primary MM cells as compared with TP53-wild-
type MM cells (47).
In vitro enforced expression of miR-34a in MM cells
To evaluate the biologic effects ofmiR-34a,we transfected
low-miR-34a MM cell lines with synthetic miR-34a or miR-
NCby electroporation. The transfection efficiencywas 98%,
as determined by FAM-dye-labeled oligonucleotide trans-
fection and subsequent flow cytometric analysis (Supple-
mentary Fig. S1A). In a parallel experiment, the biologic
activity of transfected synthetic miRNA was assessed by
downregulation of PTK9 mRNA induced by miR-1 (Sup-
plementary Fig. S1B). The antiproliferative effect inducedby
miR-34a in MM cells was evaluated by Trypan Blue exclu-
sion assay (procedure available in SupplementaryMethods)
after synthetic miR-34a or miR-NC transfection. We
observed a significant growth inhibition in TP53-mutated
SKMM1 (P < 0.005, Fig. 2A), RPMI-8226 (P < 0.05, Fig. 2B),
andOPM1(P<0.005, Fig. 2C)MMcells.On theother hand,
TP53-wild type MM1S and NCI-H929 cells, where a func-
tional TP53-miR34a loop is operative,werenot inhibited by
miR-34a (Supplementary Fig. S2), although transfection of
anti-miR-34a oligonucleotides indeed produced a growth
stimulus in these cells (Fig. 2D and E). These data further
confirm miR-34a role as a negative regulator of MM cell
growth in TP53-wild type cells, and strengthen the rationale
of our experimental strategy of enforced expression in TP53-
mutated MM cells.
We next investigated the induction of apoptosis by
Annexin V/7-AAD assay. An increase of apoptotic cell death
was observed in TP53-mutated cells following transfection
with miR-34a, but not with miR-NC, after 48 hours (Fig. 2F
and G) that was more evident in SKMM1 cells. In contrast,
this effect was not observed in TP53wild-type cells (data not
shown). To further explore the anti-MM effects induced by
miR-34a, we carried out a clonogenic assay to study the
colony formation activity of transiently transfected cells.We
found a 45% and 20% reduced SKMM1 and RPMI-8226
colony formation, respectively, 14 days after transfection
(Fig. 2H). These findings indicate that miR-34a inhibits
clonogenic properties of MM cells.
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In vitro effect of MM cell transduction with lentiviral
miR-34a expression vector
To achieve stable expression of miR-34a, the feline
immunodeficiency lentiviral miR-34a expression vector
was used to infect MM cells (for details see Supplemen-
tary Methods). About 97% transduction efficiency was
shown by flow cytometric GFP analysis (Supplementary
Fig. S3). As shown in Supplementary Fig. S3A, the stable
expression of miR-34a affected proliferation of SKMM1
cells in a time-dependent manner, as showed by MTS
assay. Consistently, we detected a 2-fold increase of early
and late apoptosis 48 hours after transduction with miR-
34a, as evidenced by Annexin/7-AAD assay (Supplemen-
tary Fig. S4B). Moreover, the miR-34a expression
levels, analyzed by q-RT-PCR after lentivirus infection,
showed 3-fold increase in pMIF-34a compared with
pMIF empty-vector transduced cells (Supplementary
Fig. S4C). These findings showed that lentivirus trans-
duction of miR-34a results in a significant anti-MM
effect in vitro.
Downregulation of validated miR-34a targets in MM
cell lines.
To investigate whether genes known to be regulated by
miR-34a were modulated by exogenous synthetic mimics,
we analyzed BCL2, CDK6, andNOTCH1mRNA levels by q-
RT-PCR in miR-34a–transfected SKMM1 and RPMI-8226
cells. As shown in Fig. 3A and B, we detected a significant
downregulation of CDK6 and NOTCH1 mRNA expression
24 hours after cell transfection. This effect occurred together
with downmodulation of CDK6 and BCL2 proteins evalu-
ated by Western blot analysis (Fig. 3C and D). Altogether,
these results show that synthetic miR-34a activity modu-
lates validated targets.
miR-34a lentiviral transduction inhibits MM xenograft
formation in SCID mice
In the in vivo studies,we examined the effect of transduced
miR-34a on the tumorigenic potential of TP53-mutated
MM cells engrafted in SCID mice (for in vivo experiments
see Supplementary Methods). As shown in Fig. 4A,
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Figure 1. miR-34a expression and nutlin-3 response in MM cell lines.
A, q-RT-PCR analysis of miR-34a using total RNA from 2 MM cell lines
bearing wild-type TP53 and 9 MM cell lines with mutated TP53.
B, q-RT-PCR of miR-34a in nutlin-3–treated (10 mmol/L) RPMI-8226,
SKMM1 (TP53 mutated), and NCI-H929 (TP53 wild-type) cells.
Raw Ct values were normalized to RNU44 housekeeping snoRNA
and expressed as DDCt values calculated with respect to miR-34a
levels in RPMI-8226 cells, using the comparative Ct method.
Values represent mean observed in 4 different experiments SD.
miR-34a expression was signiﬁcantly higher in TP53-wt versus
TP53-mutated MM cells (P ¼ 0.045). C, Western blotting of BCL2,
CDK6, and TP53 protein in TP53 mutated RPMI-8226 and TP53
wild-type NCI-H929 cells 24 hours after nutlin-3-treatment.
The protein loading control was g-tubulin. A representative
of 3 experiments is shown.
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enhanced expression of miR-34a caused a significant
inhibition (P < 0.05) of tumor formation. In addition, the
average size ofmiR-34a transduced tumorswas significantly
(P ¼ 0.008) lower compared with control group. Quanti-
tative analysis of miR-34a levels in retrieved tumors con-
firmed amore than3-fold increase in pMIF-34a–transduced
tumors (Supplementary Fig. S5A). Histologic and immu-
nohistochemical analysis of excised pMIF-34a tumors dis-
closed large areas of necrosis with abundant nuclear debris
("dust-like" nuclear fragments, Fig. 4B). Moreover, few
viable cells at the tumor periphery exhibited cleaved cas-
pase-3 and lower expression of Ki-67, indicating that miR-
34a expression inhibits proliferation and stimulates the
apoptotic cascade in SKMM1 xenografts. Analysis of
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Figure 2. miR-34a has antiproliferative activity and induces apoptosis in MM cell lines. Cell growth analysis of SKMM1 (A), RPMI-8226 (B), or OPM1
(C) cells transfected with miR-34a or miR-NC oligonucleotide control. Average SD values of 3 independent experiments are plotted. P values
calculated by Student t test, 2-tailed, at 48 and 72 hours, respectively, after transfection, are: 0.01 and 0.005 for SKMM1; 0.001 and 0.05 for RPMI-8226;
0.006 and 0.008 for OPM1. Signiﬁcant P values (P < 0.05) are indicated by . Cell growth analysis of MM1S (D) and NCI-H929 (E) cells transfected with
miR-34a inhibitor (anti-miR-34a, Life Technologies AM11030) and anti-miR-scrambled inhibitor (NC, Life Technologies AM17010) oligonucleotide
control. Average SD values of 3 independent experiments are plotted. P values calculated by Student t test, 2-tailed, were 0.04 and 0.002 for MM1S
cells at 48 and 72 hours after transfection; and 0.04, 0.01, and 0.0008 for NCI-H929 cells at 24, 48, and 72 hours after transfection. Annexin V/7-AAD
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experiments are indicated. In all the experiments, P value was 0.03 comparing miR-34a versus NC. A representative image of miR-34a and NC
SKMM1 colonies shows homogeneous features of colonies formed by transfected cells with miR-NC, whereas cells transfected with miR-34a form
irregular heterogeneous colonies.
Di Martino et al.
Clin Cancer Res; 18(22) November 15, 2012 Clinical Cancer Research6264
on May 23, 2016. © 2012 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst October 3, 2012; DOI: 10.1158/1078-0432.CCR-12-1708 
miR-34a targets at mRNA and protein levels showed that
lentiviral-mediated ectopic expression of miR-34a induced
BCL2, CDK6, and NOTCH1 downregulation in pMIF-34a–
transduced tumors (Fig. 4C). Although BCL2 mRNA was
downregulated in retrieved tumors, electroporation of
miR-34a was unable to produce the same effect in vitro
(Fig. 3). On the basis of these findings, we suggest that
long-term exposure as in constitutive in vivo xenografts is
required to reduce BCL2 mRNA level, although a short-
term exposure is sufficient to impair BCL2 protein synthe-
sis. All together, these findings indicate miR-34a–depen-
dent regulation of canonical targets BCL2, CDK6, and
NOTCH1 in vivo.
Inhibition of MM xenografts in SCID mice by
intratumoral delivery of formulated miR-34a
We next investigated the effect of miR-34a treatment on
MM xenograft growth in SCID mice. miR-34a or miR-NC
were administered with NLE particles, a formulation spe-
cifically designed for systemic delivery of oligonucleotides
in vivo (33, 34). A highly significant (P < 0.0001) inhibition
of tumor growthwas detected following 4 injections (3 days
apart) of miR-34a formulated in NLE particles in SKMM1
xenografts (Fig. 5A). Importantly, after 21days,we observed
complete tumor regression in 50% of mice treated with
formulated miR-34a mimics. Furthermore, we observed a
dramatic prolongation of survival (P ¼ 0.0009) of mice
treated with miR-34a mimics compared with control
groups, with 3 mice still surviving at 6 months (180
days) when our observation ended (median survival of
miR-34a treated group was 135 days vs. 23 days in miR-
NC group; Fig. 5B). Because we did not find any differ-
ence among control groups, only scrambled oligonucleo-
tides formulated with NLE particles were used in subse-
quent experiments. Moreover, we also found a significant
antitumor effect by intratumoral injection of formulated
miR-34a in RPMI-8226 xenografts (P ¼ 0.037; Supple-
mentary Fig. S6). Therefore, we conclude that miR-34a by
intratumoral delivery is highly effective against TP53-
mutated MM xenografts and significantly prolongs host
survival.
Systemic delivery of formulated miR-34a inhibits
growth of MM xenografts in SCID mice
We next explored the systemic delivery potential of for-
mulated miR34a mimics in controlling the growth of MM
xenografts. We observed significant tumor growth inhibi-
tion (P < 0.01) in mice treated with miR-34a mimics versus
controls (Fig. 5C), and this effect was associated with
prolonged survival (P ¼ 0.041; median survival of miR-
34a treated group was 44 days vs. 26 days in miR-NC
group; Fig. 5D). Interestingly, 60%ofmiR-34a–treatedmice
were still alive at the end of observation. q-RT-PCR analysis
of miR-34a levels in excised tumors showed 4-fold increase
of miR-34a levels (Supplementary Fig. S5B). There were
large areas of necrosis with abundant nuclear debris ("dust-
like" nuclear fragments, Supplementary Fig. S7A) in miR-
34a-treated xenografts. Moreover, MM cells exhibited
cleaved caspase-3 and lower Ki-67 expression, indicating
that miR-34a treatment induced inhibition of proliferation
Figure 3. Molecular effects
induced by transient expression of
miR-34a in MM cells. q-RT-PCR of
BCL2, CDK6, and NOTCH1 after
transfection with synthetic miR-34a
ormiR-NC in SKMM1 (A) andRPMI-
8226 (B) cells. The results are shown
as average mRNA expression after
normalization with GAPDH and
DDCt calculations. Data represent
the average SD of 3 independent
experiments. Western blotting of
BCL2 and CDK6 protein in SKMM1
(C) and RPMI-8226 (D) cells 24 and
48 hours after transfection with
synthetic miR-34a or scrambled
oligonucleotides (NC). The protein
loading control was g-tubulin.
Experiments were conducted in
triplicate. miR-34a effects on
protein levels reached statistical
signiﬁcance (P < 0.05) at all time
points.
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and triggered apoptosis inMMxenografts in vivo. Moreover,
downregulation of BCL2, CDK6, and NOTCH1 at mRNA
(Supplementary Fig. S7B) and protein level (Supplemen-
tary Fig. S7C) were detected by q-RT-PCR and Western
blotting, respectively. Notably, analysis of treated versus
control mice did not show any significant behavioral
B
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Figure 4. In vivo activity of miR-34a stably expressed in MM cells. A, in vivo tumor formation of miR-34a stably expressed in MM xenografts. Tumor volumes
were measured starting day 14 after cell injection (5 106 pMIF-34a-SKMM1 in the right ﬂank or pMIF-SKMM1 in the left ﬂank) in a cohort of 10 CB-17 SCID
mice. Following the detection of tumors, measurements were assessed by an electronic caliper in 2 dimensions every 2 to 3 days until the date of sacriﬁce or
death of the ﬁrst animal. The tumor volumewas calculated as detailed inMaterials andMethods. A representativemouse image is inserted in the graph. Tumor
weight averages between pMIF-34a-SKMM1 or pMIF-SKMM1 xenografts retrieved from animals at the end of experiments show a signiﬁcant difference
between miR-34a transduced tumors versus controls (P ¼ 0.008; right). Means SD weight in grams are shown. P value was calculated by Student t test,
2-tailed, of pMIF-34a versus pMIF tumor volumes. A representative image (insert) of amiR-34a retrieved tumor (left ﬂank) versus control (right ﬂank) is shown.
B, histologies and immunohistochemistry staining directed against Ki-67 and caspase-3 in pMIF-34a-SKMM1 or pMIF-SKMM1 tumors. Histologic and
immunohistochemistry micrographs are at 20-fold magniﬁcation hematoxylin and eosin (H&E) and 40-fold magniﬁcation (Casp-3 and Ki-67), respectively.
C, quantitative analysis ofBCL2,CDK6, andNOTCH1mRNA (left) andprotein (right) levels in retrievedpMIF-34a-SKMM1or pMIF-SKMM1tumors. ThemRNA
expression levels are shown as average after normalization with GAPDH and DDCt calculations. Western blot analysis in retrieved tumors was conducted as
described in Supplementary Methods. The protein loading control was GAPDH. Experiments were conducted in triplicate. miR-34a effects on protein levels
reached statistical signiﬁcance (P < 0.05).
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changes orweight loss in SCIDmice.Nopathologic changes
were detected by analysis of normal tissues including heart,
kidney, liver, andBMof treatedmice, indicating the absence
of acute toxicity induced by the use of NLE formulatedmiR-
34a mimics (data not shown). Taken together, these results
showed the anti-MM potential of miR-34a mimics admin-
istered by systemic injection, similar to the inhibition of
tumor formation by stable transfection of lentivirus miR-
34a. The observed downregulation of miR-34a validated
targets at bothmRNAandprotein levels further supports the
therapeutic potential of NLE formulated miR-34a mimics.
miR-34a overcomes the human BMM-dependent
protective effect on MM cells in vitro and in vivo
To further study the therapeutic potential of our findings
as a novel anti-MM treatment, we evaluated the effect of
miR-34a mimics on MM cells adhering to human BMSCs.
We first tested the activity of miR-34a in cocultures in vitro
where primary MM cells adhered to human MM patient-
derived BMSCs. We found that miR-34a MM cell electro-
poration overcame the supportive effect of BMSCs, as evi-
denced by inhibition of primary MM cell proliferation (Fig.
6A). We next investigated the anti-MM activity in vivo using
our recently established novel SCID-synth-hu model (43).
Specifically, we engrafted primary CD138þ cells from
advanced disease to evaluate the miR-34a activity when
tumor cells adhered to human BMSCs. Histologic and
immunohistochemical analysis of retrieved 3-dimensional
biopolymeric scaffolds after treatment with formulated
miR-34a showed reduced tumor infiltration and an increase
of cleaved caspase-3 and reduction of Ki-67 expression (Fig.
6B). These findings indicate that miR-34a overcomes the
protective role of human BMM, providing an additional
rationale for development ofmiR-34a in early clinical trials.
D
 
P < 0.05 
P < 0.005 
* * 
* 
* 
* 
* 
* 
* 
*P < 0.05 n = 7 
n = 6 
n = 6 
 
 
 
 
 
 
n = 6 
A
 
* 
* 
* 
* 
*P < 0.05 
C
 
B
 
 
n = 6 
 
 
 
 
 
n = 6 
Figure 5. Intratumoral injectionand systemic delivery ofNLE-formulatedmiR-34a inhibits tumor growth inMMxenografts inSCIDmice. A, effects of formulated
miR-34a in SKMM1 xenografts by intratumoral injections. Palpable subcutaneous tumor xenografts were repeatedly treated every 3 days, as indicated by
arrows, with 20 mg of formulated miR-34a or miR-NC (NC). As control, 2 separate groups of tumor-bearing animals were injected with vehicle alone
(MaxSuppressor In Vivo RNA-LANCEr II) or PBS. Tumors were measured with an electronic caliper every day, averaged tumor volumeSD of each group is
shown. P values were calculated of miR-34a versus miR-NC (Student t test, 2-tailed).  indicates signiﬁcant P values (P < 0.05). B, survival curves
(Kaplan–Meier) of intratumorally treated mice show prolongation of survival in miR-34a–treated SKMM1 xenografts compared with controls (log-rank test,
P ¼ 0.0009). Survival was evaluated from the ﬁrst day of treatment until death or sacriﬁce. Percentage of mice alive is shown. C, mice with palpable
subcutaneousSKMM1 tumor xenograftswere treatedwith 20mgof formulatedmiR-34a or scrambledoligonucleotides (NC) by intravenous tail vein injections.
Caliper measurement of tumors was taken every 2 days from the day of ﬁrst treatment. Averaged tumor volumes SD are reported.  indicates signiﬁcant
P values (P < 0.05). D, survival curves (Kaplan–Meier) of systemically miR-34a–treated mice show prolongation of survival compared with controls (log-rank
test, P ¼ 0.041). Survival was evaluated from the ﬁrst day of treatment until death or sacriﬁce. Percentage of mice alive is shown.
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Discussion
In this report, we show that synthetic miR-34a exerts a
powerful antitumor activity in clinically relevant xenograft
models of human MM. In vivo results were complemented
by in vitro experiments where miR-34a mimics showed
significant antiproliferative activity, apoptotic effects, and
modulation of gene expression. To our knowledge, this is
the first experimental evidence of antitumor activity ofmiR-
34a in preclinical models of MM.
An important fallout of ourwork is the successful delivery
of miR-34a mimics in MM xenografts in SCID mice and in
the SCID-synth-hu model via NLE, a novel lipid-based
delivery vehicle which overcomes many of the most impor-
tant limitations of other vehicles (34). In our study, the
NLE-formulated miR-34a was safely administered to ani-
mals by either intratumor or systemic injection. In the latter
case, the achievement of tumor growth inhibition in sub-
cutaneous xenografts is substantial and particularly rele-
vant, given the poor vascularization of rapidly growing
xenografts. Importantly, these findings indicate the optimal
bioavailability of NLE-formulated miR-34a mimics. More-
over, the miR-34a target downregulation in tumors excised
from animals treated systemically with miR-34a mimics
further confirms successful miRNA delivery. To provide the
framework for clinical translation of this experimental
approach, we further confirmed the in vivo activity of
miR-34amimics using the innovative SCID-synth-humodel
of humanMM (43–45). In this biosynthetic and orthotopic
model of human MM, tumor cells grow within a bone-like
3-dimensional biopolymeric scaffold previously engrafted
with MM patient-derived human BMSCs. In this model,
delivery of systemic miR-34a mimics induced significant
antitumor effects, as showed by immunohistochemical
analysis of retrieved scaffolds, corroborating the results
obtained with the other 2 murine xenograft models of
human MM used in this study. Most importantly, the
antitumor properties of miR-34a mimics were not attenu-
ated by the protective role of BMSCs, further highlighting
the potential for clinical translation of our findings. In
addition, the anti-MM activity ofmiR-34a occurredwithout
any evidence of toxicity in mice, suggesting a favorable
therapeutic index. Our data are in agreement with reports
by Wiggins and colleagues (33) on the safe use of formu-
lated NLE-miR-34a in experimental animals, and strongly
support clinical development of miR-34a–based strategies
in MM patients. Notably, formulated miRNA mimics are
distinct frommolecularly targeted drugs, as their antitumor
activity relies on the modulation of a wide range of genes
rather than inhibition of individual gene products. In
particular, miRNA-based therapeutics can be relevant both
for safety issues and to abrogate late onset of resistance,
because of the complexity ofmiRNA-targeted pathways and
the consequent low chance of developing individual
"escape" mutations in the treated cells.
The molecular mechanisms of antimyeloma activity of
miR34a mimics are presently under investigation. Func-
tionally, miR-34a is a component of the TP53 transcrip-
tional network; in TP53-wild-type cells, it is involved in a
feedback loop where TP53 activates miR-34a expression,
which in turn increases the activity of TP53 (31). In fact, loss
of miR-34a is associated with resistance to apoptosis
induced by TP53-activating agents (21, 24). The tumor
suppressor activity of miR-34a observed in this study seems
to be TP53-dependent, because it mainly occurs in tumors
bearing TP53-mutated gene. In this context, it is of great
interest that we found high in vivo activity of miR-34a
against SKMM1 xenografts with a TP53 inactivating
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Figure 6. miR-34a exerts anti-MM activity in cocultures of primary MM-BMSCs and in the SCID-synth-hu model. A, MTS assay conducted in CD138þ cells
from a MM patient cocultured with BMSCs, 24 hours after electroporation with synthetic miR-34a or miR-NC. Absorbance measurements SD of 3
independent experiments are shown; signiﬁcant reduction in cell survival was observed (P < 0.002, by Student t test, 2-tailed) in cocultures treated with
miR-34a. B, in vivo analysis ofmiR-34a in the SCID-synth-humodel. TP53-mutated primary CD138þMMcells were injected into 3-dimensional biopolymeric
scaffolds with BMSCs. Engrafted synthetic scaffolds were directly injected in vivo by NLE formulated miR-34a or miR-NC in 3 mice for each group.
A representative hematoxylin and eosin (H&E) and immunohistochemistry staining of Ki-67 and caspase-3 on retrieved scaffolds from treated animals is
shown (magniﬁcation 40).
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mutation but intermediate levels of miR-34a, suggesting
that the anti-MM potential of miR-34a is because of more
than just simple miRNA replacement in fully depleted cells.
Moreover, our finding that anti-miR-34a oligonucleotide
transfection in TP53 wild-type MM cells produced a growth
stimulus provides further evidence of the miR-34a role as a
negative regulator of MM cell growth and highlights the
rationale of our experimental strategy of inducing miR-34a
expression in TP53 mutated MM. The high sensitivity of
TP53-mutated MM cells is of interest, as TP53 inactivation
occurs when MM progresses to a drug-resistant and more
aggressive phenotype. Although 13% of MM patients carry
TP53 coding mutations or 17q13.1 deletion causing allelic
loss of TP53, 24% of plasma cell leukemia (PCL) patients
have TP53 coding mutations and 50% of primary PCL
patients or 75% of secondary PCL patients have 17q13.1
deletion (48–51). Furthermore, a biallelic inactivation with
both coding mutation and allelic deletion has been found
in 11% and 33% of primary or secondary PCL patients,
respectively (48, 50, 52), suggesting that the "biologically
end-stage" disease might benefit from therapies restoring
the TP53 function through miR-34a enforcement.
Of major relevance at this point is the development of
therapeutic rationally designed combinations based on the
study of the molecular mechanism of miR-34a activity. An
interesting combination may be with gamma-secretase
inhibitors taking in account NOTCH1 as relevant miR-
34a target. The molecular complexity of human MM high-
lights the need of novel miRNA-based therapeutic combi-
nations, and the present study along with previous findings
(17, 18), provides the basis for these research perspectives.
In conclusion, the successful delivery and the antitumor
activity of miR-34a mimics in clinically relevant mouse
models, together with the favorable safety profile, provide
the rationale and the framework for clinical development
of synthetic miR-34a mimics to improve patient outcome
in MM.
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